The company launched ONAPGO™, a new treatment for Parkinson's disease, in April 2025 and saw significant growth in Qelbree prescriptions, which rose by 22%. Supernus reiterated its full year ...

Onapgo will also face an immediate challenge for market share from AbbVie's (ABBV) recently approved PD drug Vyalev. Supernus' senior management team has been in place for some time - CEO Khattar ...

Early in the second quarter, we launched ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults ...

President and CEO of Supernus. “In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson ...

Supernus Pharmaceuticals Inc (SUPN) reports robust Qelbree sales and strategic advancements, despite facing increased losses ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings tomorrow after market close. Here’s what to look for. Supernus Pharmaceuticals beat analysts ...

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today ...

ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 financial guidance. ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus ...

ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 financial guidance. ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus ...